Showing results (31-40 of 57) with videos related to
Sort By:
Pageof 6
The Lancet. Oncology|October 17, 2024
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung CancerMariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.The New England Journal of Medicine|August 21, 2009
Screening for epidermal growth factor receptor mutations in lung cancerRafael Rosell, Teresa Moran, Cristina Queralt, et al.Journal for Immunotherapy of Cancer|August 27, 2021
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trialBelén Sierra-Rodero, Alberto Cruz-Bermúdez, Ernest Nadal, et al.Journal for Immunotherapy of Cancer|September 28, 2022
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapyMarta Casarrubios, Mariano Provencio, Ernest Nadal, et al.The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.Cancer Research|July 6, 2019
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLCJeffrey H Becker, Yandi Gao, Margaret Soucheray, et al.Expert Opinion on Biological Therapy|May 20, 2026
Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancerMariano Provencio, David Aguiar, Mónica Antoñanzas, et al.Nature Communications|December 23, 2025
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trialMariano Provencio, Begoña Campos, María Guirado, et al.Journal for Immunotherapy of Cancer|October 20, 2024
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancerMarta Molina-Alejandre, Francisco Perea, Virginia Calvo, et al.Pageof 6